^
    Back
    Association details:
    Biomarker:KDM1A expression
    Cancer:Small Cell Lung Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Thorac Oncol
    Title:

    Clinical benefit from immunotherapy in patients with small cell lung cancer is associated with tumor capacity for antigen presentation

    Published date:
    05/17/2023
    Excerpt:
    CheckMate 032, a multicenter, open-label, phase 1/2 trial evaluating nivolumab alone or with ipilimumab was the largest study of ICB alone in patients with SCLC....Analysis of epigenetic determinants of antigen presentation identified Lysine-Specific Demethylase I (LSD1) gene expression as a correlate of worse survival outcomes for patients treated with either nivolumab or the combination of nivolumab and ipilimumab.
    DOI:
    https://doi.org/10.1016/j.jtho.2023.05.008
    Trial ID:
    CheckMate 032